Fly News Breaks for October 22, 2015
ABBV
Oct 22, 2015 | 15:58 EDT
Morgan Stanley said the market is overreacting to the FDA's request for AbbVie to update its label for HCV treatment Viekira to reflect some severe cases of liver injury. Analyst Matthew Harrison said the cases of liver failure were identified in patients with underlying liver cirrhosis or advanced liver disease and said Viekira is unlikely to be pulled from the market.
News For ABBV From the Last 2 Days
There are no results for your query ABBV